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ABSTRACT
Glioblastoma (GBM) is the most malignant brain tumor with very limited 
therapeutic options. Standard multimodal treatments, including surgical resection 
and combined radio-chemotherapy do not target the most aggressive subtype of 
glioma cells, brain tumor stem cells (BTSCs). BTSCs are thought to be responsible for 
tumor initiation, progression, and relapse. Furthermore, they have been associated 
with the expression of mesenchymal features as a result of epithelial-mesenchymal 
transition (EMT) thereby inducing tumor dissemination and chemo resistance. Using 
high resolution proton nuclear magnetic resonance spectroscopy (1H NMR) on GBM 
cell cultures we provide evidence that the expression of well-known EMT activators of 
the ZEB, TWIST and SNAI families and EMT target genes N-cadherin and VIMENTIN is 
associated with aberrant choline metabolism. The cholinic phenotype is characterized 
by high intracellular levels of phosphocholine and total choline derivatives and was 
associated with malignancy in various cancers. Both genetic and pharmacological 
inhibition of the cardinal choline metabolism regulator choline kinase alpha (CHKα) 
significantly reduces the cell viability, invasiveness, clonogenicity, and expression of 
EMT associated genes in GBM cells. Moreover, in some cell lines synergetic cytotoxic 
effects were observed when combining the standard of care chemotherapeutic 
temozolomide with the CHKα inhibitor V-11-0711. Taken together, specific inhibition 
of the enzymatic activity of CHKα is a powerful strategy to suppress EMT which opens 
the possibility to target chemo-resistant BTSCs through impairing their mesenchymal 
transdifferentiation. Moreover, the newly identified EMT-oncometabolic network may 
be helpful to monitor the invasive properties of glioblastomas and the success of 
anti-EMT therapy.
INTRODUCTION
Glioblastoma (GBM) is the most prevalent primary 
malignant brain tumor with a median survival of less 
than two years. High levels of therapy resistance, strong 
cellular invasiveness and rapid cell growth demand 
aggressive multimodal therapies involving resection 
followed by radio-chemotherapy [1–3].
Recent evidence has pointed to the existence of 
brain tumor initiating cells in GBMs, so called brain 
tumor stem cells (BTSCs). This subpopulation of GBM 
cells with stem cell properties are considered to be the 
main cause of tumor development, progression and 
chemo-resistance also in malignant gliomas [4–7]. Recent 
studies described an important link between stem-like 
properties and the cells capacity to invade and disseminate 
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into the microenvironment. This molecular switch called 
epithelial-mesenchymal transition (EMT) enables cell 
autonomous movement and extracellular matrix digestion, 
both cardinal features of tumor stem cells [8, 9]. EMT 
has been first described in epithelial tumors, but recent 
studies could link this phenomenon to tumor progression, 
invasion and therapy-resistance in GBM [10, 11]. EMT 
is precisely orchestrated by transcriptional modulators 
of the ZEB-, TWIST- and SNAI-families and results in 
expression of the mesenchymal markers N-cadherin and 
VIMENTIN [12–17].
Most recently EMT activation was associated 
with aberrant lipid metabolism [18], elucidating the 
importance of metabolic reprogramming for mesenchymal 
transformation. Multiple genetic and metabolic pathways 
are altered during malignant transformation, leading to 
extensive cellular growth and stress resistance. Thus, 
targeting onco-metabolic networks might be regarded as 
an innovative strategy to develop personalized cancer 
therapies [19, 20].
As such, cancer cells favor to generate ATP more 
rapidly through upregulation of glycolysis instead of 
oxidative phosphorylation. This so called Warburg effect 
is the best characterized metabolic phenotype in cancer 
[21]. Furthermore, cancer cells have been described 
to increase choline metabolism, detected by elevated 
intracellular levels of phosphocholine (PC) and total 
choline derivatives [tCho, glycerophosphocholine (GPC) 
+ PC + free choline (fCho)]. The cardinal enzyme of 
choline metabolism, choline kinase alpha (CHKα), has 
been described as the main regulator of the cholinic 
phenotype and could be associated with tumor progression 
in various cancers [22–25].
Induction of the cholinic phenotype has been 
linked to malignant progression and aggressiveness in 
several cancers [26–28]. Here we suppressed EMT by 
blocking the potent EMT activator ZEB1 and analyzed 
the effect on the cellular metabolism of GBM cells using 
high resolution proton magnetic resonance spectroscopy 
(1H NMR). We identified a bidirectional link between 
EMT and choline metabolism and revealed that targeting 
CHKα is a powerful strategy to suppress EMT status and 
BTSC properties of GBM cells. Moreover, metabolites 
that are connected to EMT progression can be monitored 
with ex vivo imaging technology and therefore have strong 
potential for rapid clinical translation in tumor diagnostics 
and surveillance.
RESULTS
ZEB1 knockdown reduces the viability of GBM 
cells
In order to analyze whether epithelial to 
mesenchymal transition (EMT) affects metabolic pathways 
in GBMs, we established stable tumor models with 
suppressed expression of the core EMT activator ZEB1 
in three GBM cell lines (LN229, GBM1 and JHH520) 
through RNA interference technology. The knockdown 
efficiency was confirmed on mRNA and protein level. RT 
qPCR results showed that transduction with either shZEB1 
#1 or shZEB1 #5 resulted in a significant reduction 
of ZEB1 mRNA by 60%–80% (Figure 1A, shown for 
shZEB1 #1). Western blotting confirmed the efficacy of 
both shZEB1 shRNAs, leading to a distinctive reduction 
of ZEB1 protein levels (Figure 1B). 
Previous research of our group revealed the role 
of ZEB1 in invasion of GBM cells [10, 12]. To further 
investigate the phenotype of ZEB1 depletion, we analyzed 
the cell viability after transduction with shZEB1 #1 or 
control vector. Therefore, we performed the TiterBlue® 
viability assay with LN229, GBM1, and JHH520 shZEB1 
#1 or control cells over five consecutive days. Figure 1C 
shows that ZEB1 knockdown decreases the viability of all 
three tested GBM cell lines. 
ZEB1 knockdown alters the cellular metabolism 
of GBM cells
In order to assess whether the reduction of EMT 
influences the metabolism of GBM cells, we extracted 
water-soluble metabolites from cells with ZEB1 
suppression and control cells. The extracts were analyzed 
via 1H NMR spectroscopy and differences in the relative 
metabolite concentrations of both conditions were 
calculated. Figure 2A shows a typical spectrum of GBM 
cell metabolic extracts with the most prominent peaks 
representing lactate (Lac), alanine (Ala), acetate (Ac), 
glutamate (Glu), glutamine (Gln), glutathione (GSH), 
creatine (Cre), phosphocreatine (PCre), free choline 
(fCho), phosphocholine (PC), glycerophosphocholine 
(GPC), total choline (tCho; comprising fCho, PC and 
GPC), myo-inositol (myo), and glycine (Gly). ZEB1 
knockdown significantly (p < 0.05) alters the intracellular 
levels of multiple metabolites belonging to various 
metabolic networks including Glu, GSH, Cre, PC, tCho, 
and Gly (Supplementary Figure S1). Given the importance 
of choline metabolism in malignant transformation and its 
utility for clinical brain tumor diagnostics [29] we decided 
to focus our studies on alterations in choline derivatives.
The EMT activator ZEB1 alters choline 
metabolism by regulating choline kinase alpha 
(CHKα)
ZEB1 depletion reduced the cholinic phenotype, 
since we detected decreased amounts of the choline 
metabolites PC and tCho in ZEB1 knockdown cells. 
Representative choline metabolite peaks of 1H NMR 
spectra and corresponding relative quantifications 
are shown in Figure 2B and 2C, respectively. ZEB1 
knockdown led to a significant reduction of PC in LN229 
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(p < 0.01) and GBM1 cells (p < 0.01). Furthermore, we 
could detect a significant reduction of tCho (p < 0.01 
for LN229 and p = 0.015 for GBM1) concentrations. In 
JHH520 GBM cells, ZEB1 depletion did not significantly 
change PC or tCho concentrations. Next we wanted to 
investigate which metabolic regulator might account for 
the ZEB1-mediated alterations in choline metabolism 
and investigated the expression of the cardinal choline 
metabolism regulating enzyme CHKα. Strikingly, ZEB1 
inhibition resulted in suppressed CHKΑ mRNA expression 
in all tested cell lines (p < 0.001 for LN229, p < 0.0001 
for GBM1, and p < 0.01 for JHH520 cells) (Figure 2D). 
As CHKα phosphorylates free choline to generate PC, we 
speculate that a reduction of CHKα activity most likely 
causes the decrease of PC and tCho that we observed 
after ZEB1 knockdown. This initial observation of a 
putative ZEB1-CHKα link let us investigate whether it 
is a bidirectionally regulated loop and if targeted CHKα 
inhibition may impact the EMT properties of GBM cells.
CHKα knockdown alters choline metabolism 
similar to ZEB1 suppression
In order to test the influence of CHKα inhibition 
on EMT in GBM cells, we performed a genetic CHKα 
knockdown using short hairpin interference technology 
(shRNAs). RT qPCR analysis revealed a significant 
(p < 0.0003) reduction of CHKα gene expression of 
up to 75% (Figure 3A). 1H NMR analysis of metabolic 
extracts showed alterations in relative choline metabolite 
concentrations in shCHKα cells similar to those found 
after ZEB1 knockdown. In concordance, the PC signal 
at 3.22 ppm was highly reduced after CHKα depletion 
(Figure 3B). Further statistical analysis highlighted a 
significant reduction of PC (p < 0.05) and tCho (p < 0.05) 
in CHKα knockdown cells as compared to control 
vector transduced cells (Figure 3C). In addition, CHKα 
knockdown significantly (p < 0.05) decreased the product 
(PC) to educt (fCho) ratio of CHKα, suggesting that the 
reduced amount of PC results from CHKα suppression 
(Figure 3D). We also noticed alterations in intracellular 
concentrations of other metabolites after CHKα depletion 
as presented in Supplementary Figure S2A. CHKα 
knockdown significantly increased Cre (p < 0.05) and 
GPC (p < 0.05) and decreased Lac (p < 0.05). We further 
detected a significant increase of the Cre/PCre ratio in 
both LN229 (p < 0.05) and GBM1 (p < 0.05) shCHKα 
cells (Supplementary Figure S2B), indicating reduced 
phosphorylation of Cre by creatine kinase brain-type 
(CKB). Indeed, we could confirm decreased expression of 
CKB in LN229 (p < 0.05) and GBM1 (p > 0.05) shCHKα 
cells (Supplementary Figure S2C).
Cells that express CHKα are positive for the 
stem cell marker SOX2 and the mesenchymal 
marker VIMENTIN 
As we found a link between CHKα and the EMT 
activator ZEB1, we further analyzed if cells with CHKα 
also express other EMT/BTSC markers. We therefore 
performed fluorescence microscopy on all analyzed cell 
lines and stained for the mesenchymal marker VIMENTIN 
Figure 1: ZEB1 knockdown reduces the cell viability. GBM cell lines (LN229, GBM1 and JHH520) were transduced with 
lentiviral particles containing shZEB1 plasmids and knockdown efficiency was confirmed using RT qPCR (A) and Western blotting (B). 
(C) The cell viability of ZEB1 knockdown cells was reduced as compared to control (pLKO.1) cells. Exponential growth curves were 
calculated for each condition and displayed in the graphs. The data is represented as mean ± SD (n = 3).
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and the stem cell marker SOX2 in combination with 
CHKα (Figure 4). CHKα staining could be detected in 
the cytoplasm as well as in the nucleus of the whole cell 
population, although the expression level differed between 
cells. The transcription factor SOX2 was expressed in the 
nucleus of all cells, elucidating the immature character of 
GBM cells. VIMENTIN could be detected predominantly 
in the cytoplasm and the expression level differed between 
the cells. Most interestingly, cells with more VIMENTIN 
staining tend to have higher expression of CHKα. In the 
co-staining for SOX2 and CHKα we could not detect 
coherences, as all cells exhibit a strong SOX2 staining. Of 
note, especially in LN229 cells CHKα tends to accumulate 
in an area close to the nucleus in a puncta-like structure, 
presumably in cells undergoing cell division (Figure 4A). 
In the past, several publications could correlate CHKα 
Figure 2: EMT reduction by ZEB1 knockdown alters choline metabolism. (A) Overview of a 1H-NMR spectrum of metabolic 
extracts of GBM cells. (B) Expanded regions of 1H-NMR spectra of control and shZEB1 transduced cells showing the main choline 
metabolites. (C) Quantitation of 1H-NMR spectra for PC and tCho from metabolic extracts of ZEB1 knockdown and control cells. 
(D) Expression of CHKΑ mRNA in ZEB1 knockdown cells was measured using RT qPCR and compared to pLKO.1 transduced cells. 
Abbreviations: ppm, parts per million. The data is represented as mean ± SD (n = 3).
Oncotarget5www.impactjournals.com/oncotarget
expression with cell cycle regulation and mitosis in 
different tumor entities [30, 31]. Our results now suggest 
that there could be a correlation between cell division and 
CHKα expression in GBM as well.
Choline kinase alpha knockdown reduces the 
expression of EMT activators and neural stem 
cell markers
Given our results of a putative EMT-choline 
metabolism loop and the co-expression of CHKα and the 
mesenchymal marker VIMENTIN, we tested the influence 
of CHKα suppression on the expression of EMT associated 
genes. We found that suppression of CHKα caused a 
strong reduction of ZEB1, ZEB2, TWIST 1, SNAI1, and 
SNAI2. Quantification of RT qPCR results revealed a 66% 
reduction of ZEB1 (p < 0.001), 62% reduction of TWIST1 
(p = 0.0014) and a 53% reduction of SNAI1 (p < 0.001) 
in LN229 and a 77% reduction of ZEB1 (p < 0.0001), a 
63% reduction of ZEB2 (p < 0.0001), a 47% reduction 
of SNAI1 (p = 0.002), and a 78% reduction of SNAI2 in 
GBM1 cells (Figure 5A). ZEB1 suppression was further 
confirmed on protein level with up to 57% reduction in 
LN229 and 21% reduction in GBM1 cells (Figure 5B). 
CHKα depletion in JHH520 cells suppressed SNAI2 
mRNA expression by 76%, TWIST1 mRNA expression 
by 96% (p < 0.0001) and TWIST1 protein expression by 
up to 73% but had no effect on ZEB expression. TWIST1 
baseline protein expression in LN229 and GBM1 was too 
low to be detected. Furthermore, we assessed the influence 
of CHKα on the expression of known EMT target genes 
and found that CHKα depletion reduced the expression 
of N-cadherin by 50% in LN229 (p < 0.02) and by 65% 
in GBM1 (p < 0.05) cells. The expression of VIMENTIN 
was reduced by 83% in LN229 (p < 0.0001), by 68% in 
GBM1 (p < 0.0001), and by 38% in JHH520 (p < 0.02) 
cells with CHKα knockdown, which is in concordance 
with our immunofluorescence data. As mesenchymal cells 
are characterized by high levels of stem cells markers, we 
analyzed the expression of the neural stem cell markers 
Nestin and SOX2 in shCHKα and control cells. CHKα 
suppression significantly reduced the expression of 
NESTIN in LN229 (p < 0.0001), GBM1 (p < 0.0001) 
and JHH520 (p = 0.0024) cells and SOX2 in LN229 
(p < 0.0001) and GBM1 (p < 0.0001) cells (Figure 5C). 
Together these results provide important insight into the 
ability of CHKα to regulate the activation of EMT and the 
stem cell character of GBM cells. 
Figure 3: Choline Kinase alpha (CHKα) knockdown leads to similar alterations in choline metabolism as ZEB1 
knockdown. (A) CHKα suppression was confirmed on mRNA level by RT qPCR. (B) Expanded regions of 1H-NMR spectra of control 
and shCHKα transduced LN229 and GBM1 cells showing the main choline metabolites. (C) Quantitation of 1H-NMR spectra for PC and 
tCho from metabolic extracts of CHKα knockdown and control cells. (D) Ratio of phosphocholine and free choline (product and educt of 
CHKα). The data is represented as mean ± SD (n = 3).
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Knockdown of choline kinase alpha reduces the 
cellular viability, invasiveness and clonogenicity
Next we investigated if CHKα suppression is 
able to reduce the mesenchymal phenotype of GBM 
cells. Compared to their control counterparts, CHKα 
knockdown cells exhibit significantly reduced viability 
(Figure 5A). Furthermore, we assessed the invasive 
behavior after CHKα inhibition with modified Boyden 
chamber assays and found a 48% decrease in invading 
cells for LN229 (p = 0.011) and a 42% decrease for GBM1 
(p = 0.0082) cells (Figure 6B). Moreover, depletion of 
CHKα significantly diminished the anchorage independent 
in vitro clonogenicity of our tested neurospheres lines 
(by 90% in JHH520, p < 0.0001 and by 80% in GBM1, 
p < 0.05). Taken together, shCHKα cells exhibit fewer 
properties of mesenchymal cells than control vector 
transduced cells. Furthermore, we looked at RNA 
sequencing data of different tumor compartments which 
were identified in the Anatomic Structures ISH Survey and 
isolated by laser microdissection. Increased expression of 
CHKα could be found in the infiltrative region and the 
leading tumor edge of GBMs (Supplementary Figure S3).
Pharmacological inhibition of choline kinase 
alpha reduces the expression of the EMT 
activators ZEB1 and TWIST1 in GBM cells
Targeted suppression of EMT in cancer cells is 
of highest clinical interest as successful mesenchymal 
reprogramming appears to be crucial for the invasive 
properties of a majority of malignant cells. In a 
translational approach, we applied the CHKα-inhibitor 
V-11-0711 (Vertex Pharmaceuticals Incorporated) on 
GBM cells and tested subsequent alterations in geno- and 
phenotype. V-11-0711 has been shown to specifically 
suppress CHKα catalytic activity in breast cancer and 
HeLa cells [32, 33]. 
GBM1 and JHH520 neurospheres were treated 
with DMSO, 0.1 µM V-11-0711 or 1 µM V-11-0711 for 
48 h and metabolic extracts were analyzed by 1H NMR 
spectroscopy. As the PC signal at 3.22 ppm was highly 
reduced in the drug treated cells we confirmed the ability 
of V-11-0711 to inhibit the enzymatic activity of CHKα in 
GBM cells (Figure 7A). 
Strikingly, pharmacological suppression of CHKα 
further led to a dose dependent reduction of ZEB1 protein 
Figure 4: CHKα is co-expressed with the mesenchymal marker VIMENTIN in GBM cells. Immunocytochemical staining 
was performed for CHKα (red), VIMENTIN (green), SOX2 (green), and DAPI (blue) in LN229 (A) and JHH520 (B) cells. All cells 
were stained positive for the three tested proteins. VIMENTIN/CHKα/DAPI and SOX2/CHKα/DAPI co-stainings revealed that CHKα 
expression correlates with the expression of VIMENTIN but not with SOX2 in all tested cell lines. Scale bar: 50 µm; GBM1 not shown.
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in GBM1 and both ZEB1 and TWIST1 protein in JHH520 
cells (Figure 7B). Additionally, V-11-0711 induced a dose 
dependent increase of CHKα protein in GBM1 but not in 
JHH520 cell line. 
Pharmacological inhibition of choline kinase 
alpha reduces the viability, invasiveness and 
clonogenicity of GBM cells
Next we wanted to prove that pharmacological 
inhibition of CHKα can resemble the effect of our genetic 
inhibition model. Strikingly, treatment with 1 µM or 
10 µM V-11-0711 for 48 h drastically reduced the cell 
viability of GBM1 and JHH520 cells (Figure 8A) which 
we could associate with dose-dependent induction of 
apoptosis (Figure 8B). For the following in vitro invasion 
and clonogenicity assays we therefore used V-11-0711 
concentrations which induce no (0.47 µM for GBM1) or 
only mild apoptosis (0.2 µM for JHH520). We performed 
modified Boyden chamber transwell assays for 24 h in the 
presence of either V-11-0711 or DMSO. The cells were 
preincubated with indicated concentrations of the drug for 
24 h. Two representative pictures and statistical analysis of 
three Boyden chamber assays are shown in Figure 8C. We 
could detect a 66.5% decrease of invading cells in GBM1 
(p = 0.0018) and a 44.3% decrease in JHH520 (p = 0.027) 
cells after drug exposure as compared to controls. 
Moreover, the capacity of the cells to form colonies was 
reduced significantly by 90% in GBM1 (p < 0.0001) and 
by 88% in JHH520 (p < 0.005) cells following treatment 
with V 11-0711. In summary, our results unequivocally 
prove the potential of CHKα inhibition to precisely target 
the invasive and clonogenic population of GBM cells by 
suppressing key EMT activators and EMT target genes.
Figure 5: Suppression of CHKα reduces the expression of EMT-associated genes and neural stem cell markers. 
(A) ZEB1, ZEB2, SNAI1, SNAI2, TWIST1, N-cadherin, and VIMENTIN mRNA levels were analyzed by RT qPCR in shCHKα cells and 
compared to controls. (B) ZEB1, TWIST1, and CHKα protein expression levels were detected using immunoblotting in shCHKα and 
control cells. (C) Nestin and SOX2 mRNA expression levels in shCHKα cells were analyzed by RT qPCR and compared to control cells. 
The data is represented as mean ± SD (n = 3).
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Combination treatment with temozolomide and 
V-11-0711 has synergistic effects in a subset of 
GBM cell lines 
ZEB1 has been associated with chemo resistance in 
GBMs [11]. In order to assess if CHKα inhibition induces 
sensitivity to the standard chemotherapeutic in GBM 
therapy, temozolomide (TMZ), GBM1 and JHH520 cells 
were treated with either single drugs or drug combinations 
of V-11-0711 and TMZ. Interestingly, treatment of GBM1 
cells with V-11-0711 and TMZ together had synergistic 
anti-growth effects in all tested drug combinations 
(correlation index < 1) (Figure 9), whereas for JHH520 
we could not detect constant synergy.
Figure 6: CHKα knockdown reduces the viability, invasiveness and clonogenicity of GBM cells. (A) Knockdown of CHKα 
reduces the viability of LN229 and GBM1 cells. Exponential growth curves were calculated for each condition and displayed in the graphs. 
(B) Cells with impaired CHKα expression are less invasive as assessed with modified Boyden chamber assays for 24 h. Representative 
pictures of hematoxylin stained invaded cells and quantifications of three Boyden chamber experiments are shown (*p < 0.05). (C) CHKα 
suppression reduces the clonogenicity of JHH520 and GBM1 cells as assessed by soft agar assays. Representative pictures of NBT stained 
colonies and quantifications of three colony forming assays are shown (*p < 0.05). Abbreviations: HPF, high power field; NBT, 4-Nitro blue 
tetrazolium chloride. The data is represented as mean ± SD (n = 3).
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DISCUSSION
In this study we could show for the first time that 
EMT can be reduced by targeting choline metabolism in 
GBM. Both genetic reduction through RNA interference 
and pharmacological inhibition of CHKα with the small 
molecule inhibitor V-11-0711 in GBM cells significantly 
reduced the expression of EMT activators and EMT 
target genes. Furthermore, we observed impaired cellular 
invasiveness, clonogenicity, viability as well as reduced 
expression of neural stem cell markers, all hallmarks of 
EMT [12], upon interfering with choline metabolism.
Our approach was to study whether EMT is 
associated with metabolic processes in GBM cells. We 
therefore used a previously described EMT inhibition 
model based on knockdown of ZEB1 [12]. In our model 
we observed decreased cell viability and changes in 
various intracellular metabolite concentrations in cells 
with reduced ZEB1. The role of ZEB1 in cell proliferation 
and tumor growth is not fully understood. A hallmark 
paper investigating the role of ZEB1 in gliomagenesis 
reported doubling of proliferation upon ZEB1 impairment 
[11], although changes in ZEB1 caused by activation 
of WNT signaling had no effect on proliferation [10]. 
Similarly, contrary results are published in other systems 
showing that ZEB1 promotes [34, 35], impairs [36, 37], 
or has no effect [38] on proliferation and cellular growth. 
On the metabolite level we observed a significant decrease 
of PC and tCho in LN229 and GBM1 cells (Figure 2). 
High concentrations of PC and tCho, also referred to as 
the cholinic phenotype, could be correlated with malignant 
transformation in various types of cancers [27, 28], 
thus our results hint at reduced malignancy after EMT 
inhibition. We found that the molecular cause for the 
reduced cholinic phenotype is impaired CHKα expression 
in cells with EMT suppression, both confirmed on mRNA 
and protein level. Also in breast cancer, CHKα activity 
has been described as the main regulator of the cholinic 
phenotype [22]. CHKα catalyzes the phosphorylation of 
free choline to PC during the synthesis of the membrane 
lipid phosphatidylcholine, thus CHKα is of highest 
importance for the integrity of the cell membrane and a 
variety of signaling pathways involving membrane lipids 
and membrane anchored proteins [39, 40]. As expected, 
Figure 7: Treatment with the choline kinase inhibitor V-11-0711 alters choline metabolism and reduces the expression of 
the EMT activators ZEB1 and TWIST1 in GBM cells. (A) Expanded regions of 1H-NMR spectra for the main choline metabolites 
of DMSO and V-11-0711 treated cells show the effectiveness of V-11-0711 treatment (B) V-11-0711 treatment led to a suppression of 
ZEB1 and induction of CHKα protein in GBM1 and a suppression of both ZEB1 and TWIST1 protein in JHH520 cells as measured by 
immunoblotting. Alpha tubulin and beta actin immunoblotting were used as loading controls. Abbreviations: DMSO, dimethyl sulfoxide. 
The data is represented as mean ± SD (n = 3).
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direct suppression of CHKα through RNA-interference 
reduced the cholinic phenotype to levels similar or even 
lower than observed after ZEB1 suppression (Figure 3). 
Taken together, these results suggest that the activity of 
CHKα is associated with EMT in GBM cells. CHKα is 
broadly expressed in our tested cell line models (Figure 4). 
This is not surprising as CHKα catalyzes important steps 
during membrane lipid synthesis and thus appears to be 
indispensable for the cell survival and proper function. 
Our co-labeling experiments revealed that cells with high 
Figure 8: V-11-0711 treatment reduces the viability, invasiveness, and clonogenicity of GBM cells. (A) Cell viability was 
impaired by V-11-0711 treatment in a dose dependent manner. Exponential growth curves were calculated for each condition and displayed 
in the graphs. (B) V-11-0711 induces apoptosis as assessed with the Muse® Annexin V and Dead Cell Kit. Pharmacological inhibition 
of CHKα with 0.47 µM (GBM1) and 0.2 µM (JHH520) V-11-0711 led to diminished invasive capacity (C) of GBM1 and JHH520 cells 
(*p < 0.05) and decreased the in vitro clonogenicity (*p < 0.005) (D). Abbreviations: DMSO, dimethyl sulfoxide; NBT, 4-Nitro blue 
tetrazolium chloride. The data is represented as mean ± SD (n = 3).
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levels of CHKα express high levels of the EMT target 
gene VIMENTIN [15–17]. Furthermore, we detected 
strong expression of the neural and glioma stem cell 
marker SOX2 [41, 42] in all our tested models. We could 
not detect any differences in SOX2 expression in cells 
with high or low levels of CHKα. 
Interestingly, CHKα knockdown reduced the protein 
expression of the EMT activator ZEB1 in LN229 and 
GBM1 cells and TWIST1 in JHH520 cells (Figure 5).
These results indicate that there is a bidirectional link 
between EMT and choline metabolism in GBM and 
that CHKα regulates EMT in a global way affecting the 
expression of several EMT activators. This hypothesis was 
further corroborated by the reduced ZEB1, ZEB2, SNAI1, 
SNAI2 and TWIST1 mRNA levels as well as lowered 
expression of EMT targets N-cadherin and VIMENTIN 
after CHKα knockdown [15–17]. Probably as a result 
of the reduced expression of EMT associated genes, 
cells with CHKα suppression exhibit fewer phenotypic 
properties of mesenchymal cells, since we detected 
significantly reduced invasiveness and clonogenicity in 
shCHKα cells (Figure 6). Concisely, ZEB1, ZEB2, and 
TWIST1 have all been described to promote invasion, 
and clonogenicity in GBM and other tumors [12, 43–48]. 
Additionally we found increased CHKα expression on the 
infiltrative leading edge of GBMs as compared to tumor 
parenchyma, indicating CHKα expression is associated 
with invasive properties of the tumor cells in GBM patients 
(Supplementary Figure S3). Taken together, this led us 
hypothesize that CHKα suppression is able to suppress the 
EMT phenotype in GBM. Of note, previous studies with 
breast cancer and ovarian cancer cells correlated CHKα 
expression with increased cellular invasiveness, migration, 
and proliferation [23, 49], indicating the importance of 
CHKα as a regulator of the mesenchymal phenotype in 
other tumors than GBM.
EMT has been associated with cancer stemness 
in a variety of tumors [8, 9]. Along with the impaired 
in vitro clonogenicity after CHKα blockade, we observed 
decreased expression of the stem cell genes Nestin and 
SOX2 after CHKα suppression. Both genes are established 
BTSC markers with prognostic value and clinical 
relevance [41, 50]. 
Mesenchymal transformation is crucial for 
the generation of chemo- and radioresistant BTSCs 
in malignant brain tumors [51, 52], thus identifying 
achievable approaches to inhibit EMT is of highest 
clinical interest. Given our evidences from the genetic 
studies that CHKα controls mesenchymal differentiation, 
we tested the effect of compound based CHKα inhibition 
using the CHKα inhibitor V-11-0711 which recently has 
been shown to selectively inhibit CHKα activity [32, 33]. 
Analysis of metabolic extracts with 1H NMR spectroscopy 
proved the enzyme inhibiting capability of V-11-0711 in 
GBM cells as we did not detect any CHKα product - PC 
at 3.22 ppm – after drug exposure (Figure 7). Strikingly, 
V-11-0711 treatment reduced the expression of the EMT 
activator ZEB1 in GBM1 and both ZEB1 and TWIST1 in 
JHH520 cells in a dose-dependent fashion. Furthermore, 
we detected a significant reduction in cellular viability, 
survival, invasiveness, and clonogenicity after drug 
treatment, confirming our data with genetic CHKα 
inhibition. Since V-11-0711 dose dependently induces 
apoptosis in GBM cells we used drug concentrations 
for the invasion and colony forming assays inducing no 
(GBM1) or very mild (JHH520) apoptosis. We further 
detected a dose dependent increase of the CHKα protein 
level in GBM1 cells, indicating a rescue mechanism 
probably triggered by the dramatically decreased PC 
concentrations. This also suggests that not the protein level 
but rather the enzymatic activity of CHKα is crucial for 
EMT regulation in GBM. Therefore, CHKα suppression 
could be a novel approach to precisely target highly 
invasive cancer stem cells. Of note, comprehensive CHKα 
inhibition through systemic administration of V-11-0711 
or other inhibitors will impair the cell membrane synthesis 
in all cells and phenotypic effects will not be limited to 
the cancerous lesions. Therefore we envision that this 
Figure 9: Combinatory treatment with Temozolomide and V-11-0711 has synergistic effects in GBM1 cells. V-11-0711 
in combination with TMZ led constantly to synergistic cytotoxic effects in GBM1 but not in JHH520 cells (*p < 0.05). Abbreviations: 
DMSO, dimethyl sulfoxide; CI, Combination Index (CI < 1, synergistic; CI = 1, additive; CI >1, antagonistic); [xy], multiple of the single 
TMZ (x) and V-11-0711 (y) dose; Single TMZ dose (x): 17.5 µM for GBM1 and JHH520; Single V-11-0711 doses (y): 0.47 µM for GBM1 
and 0.2 µM for JHH520.
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potential form of therapy could be applicable as local 
therapy in the open resection cavity or continuous through 
convection enhanced delivery through intratumoraly 
implanted catheters to target the disseminated single cells 
in the next vicinity. Another possibility could be highly 
selective intra-arterial transfer of siRNAs or shRNAs 
through cerebral circulation over the blood brain barrier 
(BBB) to the side of the tumor to suppress CHKα by 
means of RNA interference. It has been described recently 
that viruses can be transported over the BBB after osmotic 
disruption using mannitol. This superselective intra-
arterial cerebral infusion technique is already in use for 
the treatment of patients with recurrent malignant glioma 
in a phase I study and would present an alternative way 
to suppress CHKα independent from pharmacological 
compounds [53, 54]. We were able to successfully monitor 
CHKα and EMT inhibition through reduced intracellular 
PC and tCho, both after genetic modification of the cells as 
well as after drug application using non-invasive 1H NMR 
spectroscopy. This ex vivo metabolic imaging technology 
raises the interesting option to potentially monitor the 
EMT-status in cells by quantifying their intracellular 
choline concentrations. In vivo proof of principle 
experiments are necessary to assess whether this concept 
might be applied for GBM diagnostics and therapeutic 
treatment surveillance.
The exact mechanism of CHKα-dependent 
suppression of EMT activators and reduction of GBM 
cell growth, invasiveness, and clonogenicity remains 
to be investigated. However, choline metabolism and 
especially CHKα activity has been correlated with 
malignant progression in various cancers [24, 32, 55, 56]. 
In the past, the RAS signaling pathway was found to 
regulate CHKα expression during tumor progression 
via phosphoinositide 3-kinase (PI3K) [55, 57, 58], thus 
directly linking CHKα activity to known oncogenes and 
signaling pathways driving tumor progression. Also EMT 
is regulated by Ras and PI3K signaling [59–61], making 
an indirect connection between choline metabolism and 
EMT regulation possible. Furthermore, a most recent 
study of Hu et al. described CHKα itself to be an important 
player in EGFR/PI3K/AKT signaling in colorectal 
cancer. Therefore, CHKα-mediated EMT induction via 
activation of EGFR/PI3K/AKT signaling could be a 
possible explanation for our observations but of course 
needs further investigations [62, 63]. As previous studies 
showed that CHKα overexpression increases cellular 
invasiveness, drug resistance and metastasis formation 
[25, 49], establishing a CHKα overexpression model in 
GBM would be a desirable way to further analyze the 
reciprocal regulation between choline metabolism and 
EMT in the future.
EMT activation in cancer cells is associated with 
increased chemotherapeutic resistance [64–66]. We found 
that combinatory treatment with the standard of care 
chemotherapeutic temozolomide (TMZ) and V-11-0711 
causes synergistic cytotoxic effects in GBM1 cells 
(Figure 9). Our results in JHH520 cells were inconsistent, 
indicating that not the CHKα expression level itself 
regulates drug resistance and subsequent downstream 
analyses are needed to address the exact mechanism. 
Besides the cholinic phenotype, we detected 
alterations of intracellular metabolites associated with 
other metabolic networks after EMT/CHKα inhibition 
such as increased creatine. Cre has been described as a 
putative anti-cancer agent and could be correlated with 
inhibition of tumor cell growth [67, 68]. The observed 
increase of Cre could result from reduced creatine kinase 
B (CKB) activity. CKB catalyzes the phosphorylation 
of creatine to phosphocreatine, which has been shown 
to promote tumorigenesis [69, 70]. Indeed, depletion of 
CHKα resulted in reduced mRNA expression of CKB 
and an increase of the Cre/PCre ratio (Supplementary 
Figure S2). These results further emphasize the oncogenic 
role of CHKα in cancer cells and indicate that the effect 
on cellular metabolism caused by CHKα-mediated EMT 
reduction is not only limited to choline homeostasis.
In conclusion we could identify CHKα as a powerful 
regulator of EMT in GBM cells. This opens the possibility 
to target chemotherapy resistant BTSCs through impairing 
their mesenchymal differentiation. Furthermore, we 
confirmed V-11-0711 as a potent CHKα and EMT inhibitor 
and suggest that our identified EMT-oncometabolic 
network may also be helpful to develop more tailored 
diagnostics monitoring the invasive properties of GBMs as 
well as surveilling the success of anti-EMT therapy. Given 
the importance of EMT for tumor progression and tumor 
stem cells in a variety of other tissue types, our discoveries 
could impact also other fields of oncology.
MATERIALS AND METHODS
Cell culture and V-11-0711 treatment
LN229 was purchased from American Tissue 
Culture Collection (Manassas, VA). JHH520 neurospheres 
were generously provided by G. Riggins (Johns Hopkins 
Hospital Baltimore, United States of America) and 
GBM1 neurospheres were generously provided by Dr 
Angelo Vescovi (Milan, Italy). HEK293T cells were 
also purchased from American Tissue Culture Collection 
(Manassas, VA). All cell lines were cultivated under 
standard cell culture conditions of temperature (37°C) and 
carbon dioxide (5%). GBM1 and JHH520 cell lines were 
both cultured as neurospheres in DMEM w/o pyruvate 
(Gibco) supplemented with 30% Ham’s F12 Nutrient 
Mix (Gibco), 2% serum free B27 supplement (Gibco), 
20 ng/ml human recombinant bFGF (Peprotech), 20 ng/ml 
human recombinant EGF (Peprotech), 5 µg/ml Heparin 
(Sigma Aldrich), and 1x Anti-Anti Penicillin Steptomycin 
Fungizone® mixture (Gibco). LN229 and HEK293T 
cells were propagated to monolayer growth in DMEM 
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with pyruvate (Gibco) plus 10% Fetal Calf Serum (FCS; 
Biochrome) and 1× Anti-Anti Penicillin Steptomycin 
Fungizone® mixture (Gibco). Cells were passaged 
regularly to avoid acidification of media.
All cell lines were routinely tested for the absence 
of mycoplasma contamination using the PCR-based 
Mycoplasma Test Kit I/C from Promokine and tested for 
their identity using short tandem repeat testing [71].
A stock solution of the CHKα inhibitor V-11-0711 was 
prepared in DMSO and stored at –20°C. For immunoblotting, 
cells were cultured for 48 h under general cell culture 
conditions in the presence of various concentrations of V-11-
0711 diluted in neurosphere medium. For all experiments 
with V-11-0711 we decided to use JHH520 and GBM1 cells 
as they both can be cultured without 10% serum which we 
found to interfere with the activity of small molecules.
For the combinatory treatment with TMZ and V-11-
0711, the cells were cultured with different concentrations 
of the single drugs or both in combination (Single doses of 
V-11-0711: 0.47 µM for GBM1 and 0.2 µM for JHH520; 
Single doses of TMZ: 17.5 µM). Therefore, triplicates 
of 2000 cells in 100 µl were seeded in 96 –wells and 
cultured in medium supplemented with the desired 
drug concentration. After six days the cell viability was 
determined with the CellTiter-Blue® Cell Viability Assay 
(Promega) due to the manufacturer’s instructions. The 
combination index (CI) was calculated as described 
before using the program CompuSyn (ComboSyn Inc., 
Paramus, NJ. 07652 USA) [72]. Due to the algorithm of 
the software, a CI < 1 accounts for synergistic, a CI = 1 
for additive, and a CI > 1 for antagonistic effects. The 
significance of the synergistic effect (*p < 0.05) was 
calculated compared to additive effect (CI = 1).
Generation of lentiviral particles
The third generation lentiviral packaging system 
was used for the generation of lentiviral particles as 
previously described [10]. In brief, HEK293T cells were 
transfected with the lentiviral vector of choice and three 
different packaging plasmids (pMDLgpRRE, pRSVREV 
and pMD2VSVG) using GeneJuice® Transfection Reagent 
(Merck Millipore). Virus supernatant was collected at time 
points 48 h, 72 h and 96 h post transfection. Interference 
RNA sequences against CHKα were designed with 
the software Primer3 [73] and cloned into the pLKO.1 
TRC vector (Addgene plasmid #10878, [74]). Plasmids 
containing shRNAs against ZEB1 were derived as 
described previously [12].
Quantitative real time PCR
Total RNA was extracted using the RNeasy Mini 
Kit (Qiagen) due to the manufacturer’s instructions. The 
RNA concentration was photometrically assessed using 
the Nanodrop2000 spectrometer (Thermo Scientific). 
Two micrograms of RNA were utilized to synthesize 
complementary cDNA single strands using M-MLV 
reverse transcriptase (Promega) and random hexameric 
primers. Quantitative real time PCR was carried out using 
the Sso Advanced SYBR Green Supermix (BioRad) in a 
CFX Connect Thermocycler (BioRad). A total of 10 ng 
cDNA and 10 pmol per primer were used in each qPCR 
reaction. The relative quantifications were normalized 
to the endogenous housekeeping genes β-actin and β-2-
microglobulin. Calculation of normalized relative gene 
expression was performed by supplied software of the CFX 
Connect Real-Time PCR Detection System (Bio-Rad). 
The figures show data from three independent experiments 
represented as mean ± SD. An unpaired student t test was 
performed to calculate statistical significance. The Primer 
sequences can be found in Supplementary Table S1.
Western blotting
Cells were lysed in ice-cold RIPA buffer and protein 
concentrations were determined using the DC Protein 
Assay Kit (BioRad). Incubation with primary antibodies 
against ZEB1 (1:2000, Sigma #HPA027524), CHKα 
(1:500, Abcam #ab88053), TWIST1 (1:100, Santa Cruz 
#sc-81417), β-actin (1:1000, Santa Cruz #sc-130657) 
and α-tubulin (1:10000, Sigma #T9026) was performed 
overnight at 4°C on a 3D-shaker in 5% milk powder (Carl 
Roth) in TBST. As secondary antibodies we used goat-anti-
rabbit IRDye800CW (1:10000, LI-COR #926-32211), goat-
anti-mouse IRDye680RD (1:10000, LI-COR #926-68070) 
and goat anti-rabbit-HRP (1:10000, Jackson Immuno 
Research #111-035-144) diluted in blocking solution and 
incubated for 1 h at room temperature. Signal detection 
was performed either on a film based system by applying 
Super Signal West Pico Chemiluminescent Substrate 
(Thermo Scientific) or on a luminescence based system in 
a LI-COR Odyssey CLx Imager (LI-COR). Densitometry 
was done using supplied software from LI-COR or ImageJ 
software [75]. Densitometry values for ZEB1 and CHKα 
were normalized to the corresponding alpha tubulin values, 
TWIST1 was normalized to beta actin. 
Dual-phase metabolite extraction of cell cultures
At least 5 × 106 cells were harvested, counted in 
triplicates and subjected to methanol/chloroform/water 
(1:1:1, v/v/v) dual-phase extraction as previously described 
[22, 76]. In brief, cells were washed twice with 10 ml 
ice-cold saline, resuspended in 850 µl ice-cold ddH2O 
and transferred into a prechilled glass centrifuge tube. 
A total of 4 ml of ice-cold methanol were added and the 
cells were vortexed vigorously and incubated on ice for 
15 min. Then 4 ml of ice-cold chloroform were added, 
vortexed and incubated for 10 min on ice. Finally, 3.15 
ml of chilled ddH2O were added, vortexed and incubated 
at 4°C overnight to enable phase separation. Next day, 
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the samples were centrifuged for 30 min at 4500 rpm at 
4°C, and the upper phase containing the water soluble 
metabolites was carefully separated, supplemented with 
10 mg of Chelex® 100 resin (Sigma Aldrich) and incubated 
on ice for 10 min to remove divalent cations. After filtration 
through a 70 µm mesh the samples were centrifuged for 
1 h in a vacuum concentrator at 30°C to evaporate the 
methanol. Subsequently, the samples were frozen at −80°C, 
lyophilized and stored at −80°C until measurement.
1H NMR data acquisition and processing
The lyophilisates were resuspended in 20 mM 
phosphate buffer (pH 7.0) containing 10% D2O and 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS; euriso-
top) or 3-(Trimethylsilyl) propanoic acid (TSP; Lancaster 
Synthesis) as an internal standard. 
1H NMR spectra of extracts were acquired on a 
Bruker AVANCE III HD 700 spectrometer equipped 
with a 5 mm HCN TCI cryo-probe operating at 700 MHz 
(16.4 Tesla). The 1H-NMR data were obtained using 
excitation sculpting for water suppressing and the following 
acquisition parameters: 25°C sample temperature, 9800 Hz 
sweep width, 3.2 s repetition time and time-domain data 
points of 32 K and 256 transients.
Spectra were processed and analyzed using 
Mestrenova version 8.0.1-10878 (Mestrelab Research .L.). 
Metabolite intensities of different samples were 
normalized to a standard of the same concentration in 
each measurement. The figures show data from three 
independent experiments represented as mean ± SD. 
Furthermore, an unpaired student t test was performed to 
calculate statistical significance.
Double immunofluorescence stainings
LN229, GBM1, and JHH529 cells were plated onto 
coverslips in 24-well plates. For GBM1 and JHH520 cells, 
the coverslips were pre-coated with 50 µg/ml laminin 
(Sigma) for 1 h at 37°C. After three hours incubation at 
37°C and 5% CO2, the cells were washed with PBS and 
fixed with 4% Paraformaldehyde in PBS for 20 min at 
RT. The cells were washed again with PBS and incubated 
with blocking buffer (PBS pH 7.4, 10% Normal Goat 
Serum (Gibco), 0.5% TX-100, 0.05% Tween20) for 2 h 
at RT. Cells were stained with rabbit-anti-CHKα (1:250, 
Abcam # ab88053) and either mouse-anti-VIMENTIN 
(1:1000, #) or mouse-anti-SOX2 (1:100, Cell Signaling 
#4900S) primary antibodies diluted in blocking buffer 
overnight at 4°C. Secondary antibodies (goat anti-mouse 
Alexafluor488 (1:1000, Thermo Fisher #A-11029) and 
goat anti-rabbit Alexafluor594 (1:1000, Thermo Fisher 
#A-11037)) were incubated for 2 h at RT. Preparations 
were mounted in ProLong Gold + DAPI (Thermo Fisher) 
and fluorescent images were obtained by a LSM 700 
microscope, Carl Zeiss, and analyzed in ZEN software 
(Carl Zeiss). Controls were performed with omission of 
one or both primary antibodies.
Cell viability and apoptosis assays
For the assessment of cell viability, cell numbers 
were adjusted to defined concentrations (20.000 cells/ml 
for GBM1 and JHH520; 15.000 cells/ml for LN229). For 
the analysis of ZEB1 and CHKα knockdown cells we used 
cells from passages 3 to 10 post transduction to exclude 
a transient effect from viral transduction. Triplicates 
of 100 µl were plated into each well of a 96-well plate. 
On five consecutive days the relative viable cell mass 
was determined using the CellTiter-Blue® Cell Viability 
Assay (Promega) due to the manufacturer’s instructions. 
Fluorescence was measured after two h substrate 
incubation on cells using the Tecan Safire 2 Multiplate 
reader (Tecan) at 560ex/590em. Exponential growth 
curves were calculated for each condition and displayed 
in the graphs with GraphPad Prism 5 (GraphPad Software, 
Inc., USA).
In order to test if V-11-0711 treatment induces 
apoptosis in GBM cells, GBM1 and JHH520 cells 
were treated with different concentrations of V-11-0711 
for 48 h. Afterwards, the percentages of living, early 
apoptotic, late apoptotic, and dead cells were assessed 
using the “Muse® Annexin V and Dead Cell Assay Kit” 
for the Muse® cell analyzer (Merck Millipore) due to the 
manufacturer’s instructions.
Invasion and clonogenicity assays
Invasion of GBM cells was assessed with a modified 
Boyden chamber assay as described previously [12]. In 
brief, a total of 1*105 cells were plated per Matrigel (BD) 
coated insert in DMEM w/o FCS, DMEM with 10% FCS 
was added in the lower chamber. After an incubation of 
24 h the experiment was terminated and the remaining 
non-invaded cells on the upper surface of the membrane 
were removed carefully by swabbing. The filter was fixed 
with methanol (–20°C) for 10 min, washed with PBS and 
subsequently stained with hematoxylin for 5 min. After 
destaining with warm water, five pictures were taken per 
well and the stained invaded cells were counted. For the 
drug treatment experiments, cells were pretreated for 24 h 
with 1 µM (GBM1) or 0.5 µM (JHH520) V-11-0711 
in standard culture conditions before assessing their 
invasiveness in a time window of 24 h. 
For the assessment of the clonogenic capacity of 
GBM cells we performed Soft agar assays as described 
previously [71]. In brief, six-well plates were coated with 
1.5 ml of a base layer of 1% agarose (Gibco) in neurosphere 
medium and placed in 4°C for 1 h. A top layer containing 
0.6% agarose and a single-cell suspension (3500 cells/
well for GBM1 and 5000 cells/well for JHH520) in 2 ml 
neurosphere medium was plated on top of the base layer and 
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incubated at RT for 1 h. Once the cell layer was solidified 2 
ml of neurosphere medium (for V-11-0711 treatment studies 
either supplemented with drug or vehicle) were added to 
each well. Every three days 500 µl fresh medium (for V-11-
0711 treatment studies either supplemented with drug or 
vehicle) were added to each well. On day 21, 1 ml of a 
1 mg/ml 4-Nitro blue tetrazolium chloride (NBT) solution 
(Sigma Aldrich) was added and incubated overnight at 
37°C to stain the colonies. The experiments were quantified 
using the Clono Counter software [77]. 
RNA sequencing data from IVY Glioblastoma 
Project
RNA sequencing data was generated from anatomic 
structures isolated by laser microdissection. Five tumor 
structures (Leading Edge, Infiltrating Tumor, Cellular 
Tumor, Microvascular Proliferation, and Pseudopalisading 
Cells around Necrosis) were identified by H&E staining 
and compared to hyperplastic blood vessels and the 
microvascular proliferative region. A total of 122 RNA 
samples were generated from 10 tumors and used for 
sequencing. Website: © 2015 Allen Institute for Brain 
Science. Ivy Glioblastoma Atlas Project [Internet]. 
Available from: glioblastoma.alleninstitute.org.
ACKNOWLEDGMENTS
The authors thank Guido Reifenberger and 
his research team (Department of Neuropathology, 
University Medical Center Duesseldorf), Kristine 
Glunde (Department of Radiology, Johns Hopkins 
University) and Hans-Jakob Steiger (Department of 
Neurosurgery, University Medical Center Duesseldorf) 
for their support. The authors would like to thank Vertex 
Pharmaceuticals Incorporated for providing V-11-
0711. The authors acknowledge access to the Juelich-
Duesseldorf Biomolecular NMR Center that is jointly 
run by Forschungszentrum Juelich and Heinrich-Heine-
Universitaet Duesseldorf.
CONFLICTS OF INTEREST
The authors report no conflicts of interest.
GRANT SUPPORT
This work was supported by the Duesseldorf School 
of Oncology (funded by the Comprehensive Cancer Center 
Duesseldorf/Deutsche Krebshilfe and the Medical Faculty 
HHU Duesseldorf). AKS is supported by the Friedrich-
Ebert Stiftung. The work has been co-financed by the SFF 
Grants of the HHU University, Duesseldorf, Germany, 
awarded to JM and UDK (grant to UDK: # 701 301 640).
REFERENCES
 1. Stupp R, Hegi ME, Mason WP, van den Bent MJ, 
Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, 
Belanger K, Hau P, Brandes AA, Gijtenbeek J, et al. 
Effects of radiotherapy with concomitant and adjuvant 
temozolomide versus radiotherapy alone on survival in 
glioblastoma in a randomised phase III study: 5-year 
analysis of the EORTC-NCIC trial. The Lancet Oncology. 
2009; 10:459–466.
 2. Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, 
Tonn JC, Wick W, Weller M. Molecular diagnostics of 
gliomas: the clinical perspective. Acta neuropathologica. 
2010; 120:585–592.
 3. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, 
Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, 
Chin L, DePinho RA, Cavenee WK. Malignant astrocytic 
glioma: genetics, biology, and paths to treatment. Genes & 
development. 2007; 21:2683–2710.
 4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, 
Hide T, Henkelman RM, Cusimano MD, Dirks PB. 
Identification of human brain tumour initiating cells. 
Nature. 2004; 432:396–401.
 5. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, 
Dirks PB. Tumour-initiating cells: challenges and 
opportunities for anticancer drug discovery. Nature reviews 
Drug discovery. 2009; 8:806–823.
 6. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, 
Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression 
and chemoresistance of CD133+ cancer stem cells in 
glioblastoma. Molecular cancer. 2006; 5:67.
 7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, 
Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells 
promote radioresistance by preferential activation of the 
DNA damage response. Nature. 2006; 444:756–760.
 8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, 
Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, 
Campbell LL, Polyak K, Brisken C, et al. The epithelial-
mesenchymal transition generates cells with properties of 
stem cells. Cell. 2008; 133:704–715.
 9. Scheel C, Weinberg RA. Cancer stem cells and epithelial-
mesenchymal transition: concepts and molecular links. 
Seminars in cancer biology. 2012; 22:396–403.
10. Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, 
Bogiel T, Reithmeier T, Prinz M, Schubert J, Niedermann G, 
Brabletz T, Eberhart CG, Nikkhah G, et al. Activation of 
canonical WNT/beta-catenin signaling enhances in vitro 
motility of glioblastoma cells by activation of ZEB1 and 
other activators of epithelial-to-mesenchymal transition. 
Cancer letters. 2012; 325:42–53.
11. Siebzehnrubl FA, Silver DJ, Tugertimur B, Deleyrolle LP, 
Siebzehnrubl D, Sarkisian MR, Devers KG, Yachnis AT, 
Kupper MD, Neal D, Nabilsi NH, Kladde MP, Suslov O, 
et al. The ZEB1 pathway links glioblastoma initiation, 
invasion and chemoresistance. EMBO molecular medicine. 
Oncotarget16www.impactjournals.com/oncotarget
2013; 5:1196–1212.
12. Kahlert UD, Suwala AK, Raabe EH, Siebzehnrubl FA, 
Suarez MJ, Orr BA, Bar EE, Maciaczyk J, Eberhart CG. 
ZEB1 Promotes Invasion in Human Fetal Neural Stem Cells 
and Hypoxic Glioma Neurospheres. Brain pathology. 2015; 
25:724–732.
13. Elias MC, Tozer KR, Silber JR, Mikheeva S, Deng M, 
Morrison RS, Manning TC, Silbergeld DL, Glackin CA, 
Reh TA, Rostomily RC. TWIST is expressed in human 
gliomas and promotes invasion. Neoplasia. 2005; 7:824–837.
14. Han SP, Kim JH, Han ME, Sim HE, Kim KS, Yoon S, 
Baek SY, Kim BS, Oh SO. SNAI1 is involved in the 
proliferation and migration of glioblastoma cells. Cellular 
and molecular neurobiology. 2011; 31:489–496.
15. Praveen Kumar VR, Sehgal P, Thota B, Patil S, Santosh V, 
Kondaiah P. Insulin like growth factor binding protein 4 
promotes GBM progression and regulates key factors 
involved in EMT and invasion. Journal of neuro-oncology. 
2014; 116:455–464.
16. Lin JJ, Zhao TZ, Cai WK, Yang YX, Sun C, Zhang Z, 
Xu YQ, Chang T, Li ZY. Inhibition of histamine receptor 
3 suppresses glioblastoma tumor growth, invasion, and 
epithelial-to-mesenchymal transition. Oncotarget. 2015; 
6:17107–17120.
17. Cai JJ, Qi ZX, Chen LC, Yao Y, Gong Y, Mao Y. miR-124 
suppresses the migration and invasion of glioma cells 
in vitro via Capn4. Oncology reports. 2016; 35:284–290.
18. Sanchez-Martinez R, Cruz-Gil S, Gomez de Cedron M, 
Alvarez-Fernandez M, Vargas T, Molina S, Garcia B, 
Herranz J, Moreno-Rubio J, Reglero G, Perez-Moreno M, 
Feliu J, Malumbres M, et al. A link between lipid 
metabolism and epithelial-mesenchymal transition provides 
a target for colon cancer therapy. Oncotarget. 2015; 
6:38719–38736.
19. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. 
Nature reviews Cancer. 2004; 4:551–561.
20. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell 
metabolism. Nature reviews Cancer. 2011; 11:85–95.
21. Warburg O. On the origin of cancer cells. Science. 1956; 
123:309–314.
22. Glunde K, Jie C, Bhujwalla ZM. Molecular causes of the 
aberrant choline phospholipid metabolism in breast cancer. 
Cancer research. 2004; 64:4270–4276.
23. Granata A, Nicoletti R, Tinaglia V, De Cecco L, Pisanu ME, 
Ricci A, Podo F, Canevari S, Iorio E, Bagnoli M, 
Mezzanzanica D. Choline kinase-alpha by regulating cell 
aggressiveness and drug sensitivity is a potential druggable 
target for ovarian cancer. British journal of cancer. 2014; 
110:330–340.
24. Hernando E, Sarmentero-Estrada J, Koppie T, Belda-
Iniesta C, Ramirez de Molina V, Cejas P, Ozu C, Le C, 
Sanchez JJ, Gonzalez-Baron M, Koutcher J, Cordon-
Cardo C, Bochner BH, et al. A critical role for choline 
kinase-alpha in the aggressiveness of bladder carcinomas. 
Oncogene. 2009; 28:2425–2435.
25. Hu L, Wang RY, Cai J, Feng D, Yang GZ, Xu QG, Zhai YX, 
Zhang Y, Zhou WP, Cai QP. Overexpression of CHKΑ 
contributes to tumor progression and metastasis and predicts 
poor prognosis in colorectal carcinoma. Oncotarget. 2016.
26. Aboagye EO, Bhujwalla ZM. Malignant transformation 
alters membrane choline phospholipid metabolism of 
human mammary epithelial cells. Cancer research. 1999; 
59:80–84.
27. Ackerstaff E, Glunde K, Bhujwalla ZM. Choline 
phospholipid metabolism: a target in cancer cells? Journal 
of cellular biochemistry. 2003; 90:525–533.
28. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism 
in malignant transformation. Nature reviews Cancer. 2011; 
11:835–848.
29. Herminghaus S, Pilatus U, Moller-Hartmann W, Raab P, 
Lanfermann H, Schlote W, Zanella FE. Increased choline 
levels coincide with enhanced proliferative activity of 
human neuroepithelial brain tumors. NMR in biomedicine. 
2002; 15:385–392.
30. Ramirez de Molina A, Gallego-Ortega D, Sarmentero-
Estrada J, Lagares D, Gomez Del Pulgar T, Bandres E, 
Garcia-Foncillas J, Lacal JC. Choline kinase as a link 
connecting phospholipid metabolism and cell cycle 
regulation: implications in cancer therapy. The international 
journal of biochemistry & cell biology. 2008; 40:1753–1763.
31. Gruber J, See Too WC, Wong MT, Lavie A, McSorley T, 
Konrad M. Balance of human choline kinase isoforms 
is critical for cell cycle regulation: implications for the 
development of choline kinase-targeted cancer therapy. The 
FEBS journal. 2012; 279:1915–1928.
32. Falcon SC, Hudson CS, Huang Y, Mortimore M, Golec JM, 
Charlton PA, Weber P, Sundaram H. A non-catalytic role of 
choline kinase alpha is important in promoting cancer cell 
survival. Oncogenesis. 2013; 2:e38.
33. Mori N, Wildes F, Kakkad S, Jacob D, Solaiyappan M, 
Glunde K, Bhujwalla ZM. Choline kinase-alpha protein and 
phosphatidylcholine but not phosphocholine are required 
for breast cancer cell survival. NMR in biomedicine. 2015; 
28:1697–1706.
34. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, 
Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, 
et al. CUL4A induces epithelial-mesenchymal transition and 
promotes cancer metastasis by regulating ZEB1 expression. 
Cancer research. 2014; 74:520–531.
35. Sintov E, Nathan G, Knoller S, Pasmanik-Chor M, 
Russ HA, Efrat S. Inhibition of ZEB1 expression induces 
redifferentiation of adult human beta cells expanded 
in vitro. Scientific reports. 2015; 5:13024.
36. Liu Y, El-Naggar S, Darling DS, Higashi Y, Dean DC. 
Zeb1 links epithelial-mesenchymal transition and cellular 
senescence. Development. 2008; 135:579–588.
Oncotarget17www.impactjournals.com/oncotarget
37. Hugo HJ, Pereira L, Suryadinata R, Drabsch Y, Gonda TJ, 
Gunasinghe NP, Pinto C, Soo ET, van Denderen BJ, Hill P, 
Ramsay RG, Sarcevic B, Newgreen DF, et al. Direct 
repression of MYB by ZEB1 suppresses proliferation and 
epithelial gene expression during epithelial-to-mesenchymal 
transition of breast cancer cells. Breast cancer research : 
BCR. 2013; 15:R113.
38. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, 
Sonntag A, Waldvogel B, Vannier C, Darling D, zur 
Hausen A, Brunton VG, Morton J, Sansom O, et al. The 
EMT-activator ZEB1 promotes tumorigenicity by repressing 
stemness-inhibiting microRNAs. Nature cell biology. 2009; 
11:1487–1495.
39. Furse S, de Kroon AI. Phosphatidylcholine’s functions 
beyond that of a membrane brick. Molecular membrane 
biology. 2015; 32:117–119.
40. Cazzolli R, Shemon AN, Fang MQ, Hughes WE. 
Phospholipid signalling through phospholipase D and 
phosphatidic acid. IUBMB life. 2006; 58:457–461.
41. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, 
Malatesta P, Ravetti GL, Zona GL, Daga A, Corte G. SOX2 
silencing in glioblastoma tumor-initiating cells causes stop 
of proliferation and loss of tumorigenicity. Stem cells. 2009; 
27:40–48.
42. Favaro R, Valotta M, Ferri AL, Latorre E, Mariani J, 
Giachino C, Lancini C, Tosetti V, Ottolenghi S, Taylor V, 
Nicolis SK. Hippocampal development and neural stem 
cell maintenance require Sox2-dependent regulation of Shh. 
Nature neuroscience. 2009; 12:1248–1256.
43. Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, 
Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, 
Gonzalez-Herrero I, Sanchez-Garcia I, Silber JR, Horner PJ, et 
al. TWIST1 promotes invasion through mesenchymal change 
in human glioblastoma. Molecular cancer. 2010; 9:194.
44. Pang H, Zheng Y, Zhao Y, Xiu X, Wang J. miR-590-3p 
suppresses cancer cell migration, invasion and epithelial-
mesenchymal transition in glioblastoma multiforme by 
targeting ZEB1 and ZEB2. Biochemical and biophysical 
research communications. 2015; 468:739–745.
45. Rahme GJ, Israel MA. Id4 suppresses MMP2-mediated 
invasion of glioblastoma-derived cells by direct inactivation 
of Twist1 function. Oncogene. 2015; 34:53–62.
46. Wang N, Guo D, Zhao YY, Dong CY, Liu XY, Yang BX, 
Wang SW, Wang L, Liu QG, Ren Q, Lin YM, Ma XT. 
TWIST-1 promotes cell growth, drug resistance and 
progenitor clonogenic capacities in myeloid leukemia and 
is a novel poor prognostic factor in acute myeloid leukemia. 
Oncotarget. 2015; 6:20977–20992.
47. Liu H, Wang H, Liu X, Yu T. miR-1271 inhibits migration, 
invasion and epithelial-mesenchymal transition by targeting 
ZEB1 and TWIST1 in pancreatic cancer cells. Biochemical 
and biophysical research communications. 2016; 472:346–352.
48. Dou J, He X, Liu Y, Wang Y, Zhao F, Wang X, Chen D, 
Shi F, Wang J. Effect of downregulation of ZEB1 on 
vimentin expression, tumour migration and tumourigenicity 
of melanoma B16F10 cells and CSCs. Cell biology 
international. 2014; 38:452–461.
49. Shah T, Wildes F, Penet MF, Winnard PT, Jr., Glunde K, 
Artemov D, Ackerstaff E, Gimi B, Kakkad S, Raman V, 
Bhujwalla ZM. Choline kinase overexpression increases 
invasiveness and drug resistance of human breast cancer 
cells. NMR in biomedicine. 2010; 23:633–642.
50. Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW. 
What is the clinical value of cancer stem cell markers in 
gliomas? International journal of clinical and experimental 
pathology. 2013; 6:334–348.
51. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, 
Squire J, Dirks PB. Identification of a cancer stem cell in 
human brain tumors. Cancer research. 2003; 63:5821–5828.
52. Kahlert UD, Bender NO, Maciaczyk D, Bogiel T, Bar EE, 
Eberhart CG, Nikkhah G, Maciaczyk J. CD133/CD15 
defines distinct cell subpopulations with differential in vitro 
clonogenic activity and stem cell-related gene expression 
profile in in vitro propagated glioblastoma multiforme-
derived cell line with a PNET-like component. Folia 
neuropathologica / Association of Polish Neuropathologists 
and Medical Research Centre, Polish Academy of Sciences. 
2012; 50:357–368.
53. Foley CP, Rubin DG, Santillan A, Sondhi D, Dyke JP, 
Gobin YP, Crystal RG, Ballon DJ. Intra-arterial delivery of 
AAV vectors to the mouse brain after mannitol mediated 
blood brain barrier disruption. Journal of controlled release. 
2014; 196:71–78.
54. Janowski M, Walczak P, Pearl MS. Predicting and 
optimizing the territory of blood-brain barrier opening 
by superselective intra-arterial cerebral infusion under 
dynamic susceptibility contrast MRI guidance. Journal 
of cerebral blood flow and metabolism : official journal 
of the International Society of Cerebral Blood Flow and 
Metabolism. 2016; 36:569–575.
55. Janardhan S, Srivani P, Sastry GN. Choline kinase: an 
important target for cancer. Current medicinal chemistry. 
2006; 13:1169–1186.
56. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, 
Alger JR, Di Chiro G. Increased choline signal coinciding 
with malignant degeneration of cerebral gliomas: a serial 
proton magnetic resonance spectroscopy imaging study. 
Journal of neurosurgery. 1997; 87:516–524.
57. Ramirez de Molina A, Penalva V, Lucas L, Lacal JC. 
Regulation of choline kinase activity by Ras proteins 
involves Ral-GDS and PI3K. Oncogene. 2002; 21:937–946.
58. Ramirez de Molina A, Rodriguez-Gonzalez A, Penalva V, 
Lucas L, Lacal JC. Inhibition of ChoK is an efficient 
antitumor strategy for Harvey-, Kirsten-, and N-ras-
transformed cells. Biochemical and biophysical research 
communications. 2001; 285:873–879.
59. Wu K, Fan J, Zhang L, Ning Z, Zeng J, Zhou J, Li L, 
Chen Y, Zhang T, Wang X, Hsieh JT, He D. PI3K/Akt to 
Oncotarget18www.impactjournals.com/oncotarget
GSK3beta/beta-catenin signaling cascade coordinates cell 
colonization for bladder cancer bone metastasis through 
regulating ZEB1 transcription. Cellular signalling. 2012; 
24:2273–2282.
60. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-
to-mesenchymal transition and contribution of tumor 
microenvironment. Journal of cellular biochemistry. 2007; 
101:816–829.
61. Saitoh M, Endo K, Furuya S, Minami M, Fukasawa A, 
Imamura T, Miyazawa K. STAT3 integrates cooperative 
Ras and TGF-beta signals that induce Snail expression. 
Oncogene. 2016; 35:1049–1057.
62. Zhong Z, Hu Z, Jiang Y, Sun R, Chen X, Chu H, Zeng M, 
Sun C. Interleukin-11 promotes epithelial-mesenchymal 
transition in anaplastic thyroid carcinoma cells through PI3K/
Akt/GSK3beta signaling pathway activation. Oncotarget. 2016.
63. Cheng JC, Auersperg N, Leung PC. EGF-induced EMT 
and invasiveness in serous borderline ovarian tumor cells: a 
possible step in the transition to low-grade serous carcinoma 
cells? PloS one. 2012; 7:e34071.
64. Shang Y, Cai X, Fan D. Roles of epithelial-mesenchymal 
transition in cancer drug resistance. Current cancer drug 
targets. 2013; 13:915–929.
65. Singh A, Settleman J. EMT, cancer stem cells and drug 
resistance: an emerging axis of evil in the war on cancer. 
Oncogene. 2010; 29:4741–4751.
66. Sui H, Zhu L, Deng W, Li Q. Epithelial-mesenchymal 
transition and drug resistance: role, molecular mechanisms, 
and therapeutic strategies. Oncology research and treatment. 
2014; 37:584–589.
67. Miller EE, Evans AE, Cohn M. Inhibition of rate of tumor 
growth by creatine and cyclocreatine. Proceedings of the 
National Academy of Sciences of the United States of 
America. 1993; 90:3304–3308.
68. Campos-Ferraz PL, Gualano B, das Neves W, Andrade IT, 
Hangai I, Pereira RT, Bezerra RN, Deminice R, 
Seelaender M, Lancha AH. Exploratory studies of the 
potential anti-cancer effects of creatine. Amino acids. 2016.
69. Wallimann T, Tokarska-Schlattner M, Schlattner U. The 
creatine kinase system and pleiotropic effects of creatine. 
Amino acids. 2011; 40:1271–1296.
70. Loo JM, Scherl A, Nguyen A, Man FY, Weinberg E, Zeng Z, 
Saltz L, Paty PB, Tavazoie SF. Extracellular metabolic 
energetics can promote cancer progression. Cell. 2015; 
160:393–406.
71. Kahlert UD, Suwala AK, Koch K, Natsumeda M, Orr BA, 
Hayashi M, Maciaczyk J, Eberhart CG. Pharmacologic Wnt 
Inhibition Reduces Proliferation, Survival, and Clonogenicity 
of Glioblastoma Cells. Journal of neuropathology and 
experimental neurology. 2015; 74:889–900.
72. Martin KJ, Chen SF, Clark GM, Degen D, Wajima M, 
Von Hoff DD, Kaddurah-Daouk R. Evaluation of creatine 
analogues as a new class of anticancer agents using freshly 
explanted human tumor cells. Journal of the National 
Cancer Institute. 1994; 86:608–613.
73. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, 
Remm M, Rozen SG. Primer3—new capabilities and 
interfaces. Nucleic acids research. 2012; 40:e115.
74. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, 
Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, 
Carpenter AE, Foo SY, Stewart SA, et al. A lentiviral RNAi 
library for human and mouse genes applied to an arrayed 
viral high-content screen. Cell. 2006; 124:1283–1298.
75. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to 
ImageJ: 25 years of image analysis. Nature methods. 2012; 
9:671–675.
76. Tyagi RK, Azrad A, Degani H, Salomon Y. Simultaneous 
extraction of cellular lipids and water-soluble metabolites: 
evaluation by NMR spectroscopy. Magnetic resonance in 
medicine. 1996; 35:194–200.
77. Niyazi M, Niyazi I, Belka C. Counting colonies of 
clonogenic assays by using densitometric software. 
Radiation oncology. 2007; 2:4.
